Enanta Pharmaceuticals Appoints Pharmaceutical Veteran David Poorvin, Ph.D. to Board of Directors and Announces Key Hire to Clinical Development Team

Feb 22, 2005, 00:00 ET from Enanta Pharmaceuticals

    WATERTOWN, Mass., Feb. 22 /PRNewswire/ -- Enanta Pharmaceuticals, Inc.
 today announced that David Poorvin, Ph.D. has been named to the Company's
 Board of Directors.  Dr. Poorvin brings more than 30 years of experience in
 the pharmaceutical industry to Enanta's Board.
     "David Poorvin brings vast pharmaceutical industry experience and an
 outstanding track record in both business development and clinical research.
 We look forward to David's contributions to the Board and his strategic
 insight and perspective as the Company continues to expand its product
 pipeline and advance its product candidates toward the market," stated Jay R.
 Luly, Ph.D., President, Chief Executive Officer and Director of Enanta
     Dr. Poorvin spent over twenty years at Plough Corporation, serving in a
 variety of leadership roles, including Vice President of Business Development
 and Director of Clinical Research.  Prior to Schering Plough, he served as
 Director of Clinical Research at Pfizer.  During his 14-year business
 development tenure at Schering Plough he was involved in negotiating
 significant licenses and joint ventures as well as the acquisition of numerous
 pharmaceutical products and technologies.  He received a B.A. degree from
 Hunter College of the City University of New York and his Ph.D. from Rutgers
 University, where he was awarded a post-doctoral fellowship in cardiovascular
     Additionally, Enanta announced today that Dr. Maria Paris, M.D. will join
 Enanta as Senior Medical Director. Prior to joining Enanta, Dr. Paris held
 various clinical development positions at Abbott Laboratories from 1998 to
 2004, most recently as Medical Director.  Dr. Paris has over 20 years of
 clinical development experience in infectious diseases and has managed Phase 1
 through Phase 4 studies for numerous anti-bacterials and anti-virals,
 including cethromycin, Omnicef(TM), and Kaletra(TM).  She received her Medical
 Degree from Autonomous College of Medical Sciences of Central America of Costa
 Rica and conducted a fellowship in Pediatric Infectious Diseases at the
 University of Texas, Southwestern Medical Center at Dallas.
     "The extensive infectious disease and medical expertise Maria brings to
 our drug development team will play an important role as we continue to expand
 our product pipeline," said Yat Sun Or, Ph.D. Senior Vice President of
 Research and Development of Enanta Pharmaceuticals. "As we continue to advance
 our lead clinical candidate EP-013420 through the clinic, Maria's clinical and
 regulatory experiences will be invaluable."
     About Enanta
     Enanta Pharmaceuticals is a research and development company that uses its
 novel chemistry approach and drug discovery capabilities to create best in
 class small molecule drugs in the anti-infective field.  The heart of Enanta
 is its commitment to innovative chemistry that surpasses traditional medicinal
 chemistry approaches. The Company's successful integration of chemistry with
 biology has created a new class of macrolide and ketolide antibiotics that
 overcome bacterial resistance. Additionally, Enanta has discovered antiviral
 agents targeted against the Hepatitis C virus (HCV). Enanta is a privately
 held company with offices in Watertown, MA.  More information about the
 company can be found at http://www.enanta.com.

SOURCE Enanta Pharmaceuticals